New study called GALA, which will evaluate the benefits of less frequent (every other day), higher dosings of Copaxone, will begin this April. This 'new'product might reach the matket by 2013.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.